Results for tag: "Bacterial Conjunctivitis"

Bacterial conjunctivitis is an eye condition that results from infection by bacteria, leading to inflammation of the conjunctiva, the thin, transparent layer of tissue covering the white part of the eye and the inner surfaces of the eyelids. In the context of the optical market, bacterial conjunctivitis has a direct impact on eye care products and services. Treatment typically involves the use of antibiotic eye drops or ointments, which are prescribed by healthcare professionals, including optometrists and ophthalmologists. The optical market encompasses the manufacturing and distribution of these treatments, as well as over-the-counter products that provide relief from symptoms. Additionally, this market includes the broader scope of eye care, with providers offering diagnostic and prescription services to manage and resolve infections. The pharmaceutical sector plays a central role within the bacterial conjunctivitis market through the development and distribution of antibacterial agents suitable for ophthalmic use. As of the last knowledge update, companies engaged in either the development or supply of treatments for bacterial conjunctivitis include Pfizer Inc., Novartis AG, Allergan, Santen Pharmaceutical Co., Ltd., and Valeant Pharmaceuticals International, Inc. These companies, along with others in the field, are instrumental in addressing the demand for effective conjunctivitis management and treatment options. Show Less Read more